343 results on '"van den Hof, S."'
Search Results
2. The daily updated Dutch national database on COVID-19 epidemiology, vaccination and sewage surveillance
3. Vaccinatiegraad COVID-19 vaccinatie Nederland, 2022
4. Epidemiologische impact en effectiviteit van COVID-19 maatregelen
5. Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients
6. Spread and Epidemiology of Clostridium difficile Polymerase Chain Reaction Ribotype 027/Toxinotype III in the Netherlands
7. Antibodies against Mumps in the Netherlands as Assessed by Indirect ELISA and Virus Neutralization Assay
8. Sero-Epidemiology of Mumps in Western Europe
9. Protecting the Vaccinating Population in the Face of a Measles Epidemic: Assessing the Impact of Adjusted Vaccination Schedules
10. The Seroepidemiology of Measles in Western Europe
11. Antibodies to Haemophilus influenzae Serotype b in the Netherlands a Few Years after the Introduction of Routine Vaccination
12. The Prevalence of Antibodies to Hepatitis A Virus and Its Determinants in the Netherlands: A Population-Based Survey
13. TB in migrants residing in the Netherlands for at least 5 years at diagnosis, 2003-2018
14. Validation of Surgical Site Infection Surveillance in The Netherlands
15. De COVID-19-epidemie: indammen en afvlakken. Bestrijdingsmaatregelen tegen piekbelasting in de zorg
16. Additional file 1 of Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients
17. Additional file 3 of Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients
18. Additional file 2 of Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients
19. Infection control measures to limit the spread of Clostridium difficile
20. De rol van kinderen in de transmissie van SARS-CoV-2
21. Geen wetenschappelijke ondergrens voor verplicht vaccineren
22. Naar een geintegreerde aanpak van infectieziekten
23. Preventie van tbc bij migranten Naar een geïntegreerde aanpak van infectieziekten
24. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands
25. Diagnostic accuracy of rapid antigen tests in pre-/asymptomatic close contacts of individuals with a confirmed SARS-CoV-2 infection
26. Vaccinatie van kinderen tegen Haemophilus influenzae type b, meningokokken en pneumokokken: huidige stand van zaken en toekomstige ontwikkelingenHaemophilus influenzae
27. Use of insurance claims and electronic health records to assess tuberculosis and latent tuberculosis diagnosis
28. Moet een volwassene die niet tegen mazelen is gevaccineerd dit alsnog laten doen?
29. 13 Het prezies-netwerk; surveillance als kwaliteitssysteem ter preventie van ziekenhuisinfecties
30. Antibiotic use and other risk factors at hospital level for outbreaks with Clostridium difficile PCR ribotype 027
31. Effect of 10 years of surveillance on the incidence of surgical site infections in the Netherlands: O137
32. Risk factors, including antibiotic use, at hospital level for outbreaks with Clostridium difficile PCR ribotype 027: O273
33. Results from the minimal dataset of the European surveillance of ICU-acquired infections (HELICS-ICU),2000–2004: P1900
34. Surgical site infections in the Helics network: results from 11 European surveillance networks: P1899
35. Elimination and Eradication of Measles: where do we stand now? Workshop of the EUPHA Section on Infectious Disease Control: Measles in the Netherlands
36. Impact of conjugated meningococcal C Vaccination in the Netherlands
37. Options for improvement of the Dutch measles vaccination schedule
38. Evaluation of the national immunisation programme in the Netherlands: immunity to diphtheria, tetanus, poliomyelitis, measles, mumps, rubella and Haemophilus influenzae type b
39. Tuberculin skin test reaction depends on type of purified protein derivative: implications for cut-off values
40. Hotspots for transmission of extensively drug-resistant tuberculosis
41. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan
42. A population-based study on tetanus antitoxin levels in the Netherlands
43. Cost-effectiveness of the Xpert® MTB/RIF assay for tuberculosis diagnosis in Brazil
44. Helminths and skewed cytokine profiles increase tuberculin skin test positivity in Warao Amerindians
45. Evidence-based interventions to reduce tuberculosis stigma: a systematic review
46. Integration of HIV testing in tuberculosis drug resistance surveillance in Kazakhstan and Kenya [Short communication]
47. Measles outbreak in a community with very low vaccine coverage, the Netherlands
48. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan
49. Risicofactoren En GezondheidsEvaluatie Nederlandse Bevolking, een Onderzoek Op GGD'en (Regenboog-project); jaarverslag 1999
50. Risicofactoren En GezondheidsEvaluatie Nederlandse Bevolking, een Onderzoek Op GGD'en (Regenboog-project); jaarverslag 2000
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.